SciELO - Scientific Electronic Library Online

 
vol.30 issue1Helicobacter Pylori Reinfection Rate after More Than Two Years of Follow-up in a Cohort of Successfully Treated Colombian PatientsA Review of Dilutional Hyponatremia and Liver Transplantation author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Gastroenterologia

Print version ISSN 0120-9957

Abstract

SANCHEZ PEREZ, Maira Patricia; VELASCO BENITEZ, Carlos Alberto  and  LOPEZ LOPEZ, Pío. Seroprotection for Hepatitis B after Three Doses of Vaccine in Colombian HIV Patients under the Age of 18. Rev Col Gastroenterol [online]. 2015, vol.30, n.1, pp.60-67. ISSN 0120-9957.

Introduction: Seroprotection against hepatitis B is defined as anti-hepatitis B surface antigen titer ≥ 10 IU/L), but in children with human immunodeficiency virus (HIV) this is low. Objective: The objective of this study was to establish SP against HBV and potential associated factors in children with HIV in Cali, Colombia. Methodology: This is a study of seroprotection against HBV in 85 children under 18 years of age after receiving three doses of vaccine. Clinical, paraclinical, environmental and sociodemographic variables were considered. Statistical analysis included estimation of proportion per occurrence, 95% confidence intervals, percentages, means, standard deviations, and univariate analysis between variable exposure and effect. Confounding factors were evaluated with 2x2 contingency tables and estimation of odds ratios with 95% confidence intervals. The Chi2 test was used with significance of p <0.05. The multivariate model used backward elimination. Variables with p> 0.10 were eliminated by likelihood-ratio test. Results: SP was 35.3% (95% CI: 25.2 to 46.4, n = 30) in children with a mean age of 101 ± 44 months. Patients were predominantly female gender and mixed race and had Stage C HIV (according to US Centers for Disease Control and Prevention (CDC) standards). Average treatment time was 5 years. No relationship was found between the time between the first, second and third doses of vaccine and SP, nor among diagnosis, time of vaccination, and SP. The multivariate model showed an association of SP with the temporal relationship between start of treatment (0-3 years), last dose of vaccination (OR = 4.3, 95% CI: 0.96 to 19.23; p = 0.05) and more than three years after starting treatment (OR = 9.69, 95% CI: 2.37 to 39.5; p = 0.00). Conclusion: The prevalence of SP was 35.3%, with a possible risk factor associated with the temporal relationship between onset of treatment and time of the last dose of vaccine

Keywords : Hepatitis B; HIV infection; seroprotection; children.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )